Icon price target raised to $367 from $357 at Truist

Truist analyst Jailendra Singh raised the firm’s price target on Icon to $367 from $357 and keeps a Buy rating on the shares after its Q4 results. The company hs seen a more solid trajectory with actual business wins so far this year, though the management also noted that during 2023, large pharmas re-engineered their models and outsourcing, which affected timing of business awards, the analyst tells investors in a research note.